Quarterly Update on Georgia CORE Breast Cancer Investigator-Initiated Trials Released

1/22/2009

Ruth O’Regan, MD, Associate Professor of Hematology and Oncology at the Emory Winship Cancer Institute, Director of Winship's Translational Breast Cancer Research Program and a Georgia Cancer Coalition Distinguished Cancer Scholar, has released the third series of an educational video program to provide updates for the Georgia CORE breast cancer trials. The educational program is funded by the Susan G. Komen for the Cure. In this video update, Dr. O’Regan provides an update on the existing Georgia CORE breast cancer trials. An update on the accrual for each trial is also discussed in the video. Dr. O’Regan also describes a new Triple Negative trial that is open at Winship Cancer Institute: Phase II Trial of Gemcitabine and Oxaliplatin for ER-, PR-, HER2Neu- (Triple Negative) Metastatic Breast Cancer. Georgia CORE Investigator-Initiated Breast Cancer Trials

• Randomized Phase II Trial of Sequential Docetaxel followed by Capecitabine versus Concomitant Docetaxel/Capecitabine as Induction Therapy for Early Stage Breast Cancer
• Phase II Neoadjuvant Trial of Trastuzumab in Combination with Dose-Dense ABI-007 (Abraxane) Followed by Vinorelbine for HER2 Overexpressing Early Stage Breast Cancer

Please click here to view the educational video. **The video requires the most recent version of Real Player.

Please click here to download the Real Player software.